Literature DB >> 22592213

Resection rate and outcome of pulmonary resections for non-small-cell lung cancer: a nationwide study from Iceland.

Hunbogi Thorsteinsson1, Asgeir Alexandersson, Gudrun N Oskarsdottir, Rut Skuladottir, Helgi J Isaksson, Steinn Jonsson, Tomas Gudbjartsson.   

Abstract

BACKGROUND: The proportion of patients with non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent is one measure of effectiveness in treating lung cancer. To the best of our knowledge, surgical resection rate (SRR) for a whole nation has never been reported before. We studied the SRR and surgical outcome of NSCLC patients in Iceland during a recent 15-year period.
METHODS: This was a retrospective study of all pulmonary resections performed with curative intent for NSCLC in Iceland from 1994 to 2008. Information was retrieved from medical records and from the Icelandic Cancer Registry. Patient demographics, postoperative tumor, node, metastasis stage, overall survival, and complication rates were compared over three 5-year periods.
RESULTS: Of 1530 confirmed cases of NSCLC, 404 were resected, giving an SRR of 26.4%, which did not change significantly during the study period. Minor and major complication rates were 37.4% and 8.7%, respectively. Operative mortality rates were 0.7% for lobectomy, 3.3% for pneumonectomy, and 0% for lesser resection. Five-year survival after all procedures was 40.7% and improved from the first to the last 5-year period (34.8% versus 43.8%, p = 0.04). Five-year survival for stages I and II together was 46.8%, with no significant change in stage distribution between periods. Five-year survival after pneumonectomy was 22.0%, which was significantly lower than for lobectomy (44.6%) and lesser resection (40.7%) (p < 0.005). Unoperated patients had a 5-year survival of 4.8%, as compared to 12.4% for all the NSCLC patients together.
CONCLUSION: Compared with most other published studies, the SRR of NSCLC in Iceland is high. Short-term outcome is good, with a low rate of major complications and an operative mortality of only 1.0%. Five-year survival improved significantly over the study period.

Entities:  

Mesh:

Year:  2012        PMID: 22592213     DOI: 10.1097/JTO.0b013e318252d022

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

Review 1.  Immune checkpoint pathways in non-small cell lung cancer.

Authors:  Young Kwang Chae; Ayush Arya; Wade Iams; Marcello Cruz; Nisha Mohindra; Victoria Villaflor; Francis J Giles
Journal:  Ann Transl Med       Date:  2018-03

2.  Combination of computer extracted shape and texture features enables discrimination of granulomas from adenocarcinoma on chest computed tomography.

Authors:  Mahdi Orooji; Mehdi Alilou; Sagar Rakshit; Niha Beig; Mohammad Hadi Khorrami; Prabhakar Rajiah; Rajat Thawani; Jennifer Ginsberg; Christopher Donatelli; Michael Yang; Frank Jacono; Robert Gilkeson; Vamsidhar Velcheti; Philip Linden; Anant Madabhushi
Journal:  J Med Imaging (Bellingham)       Date:  2018-04-18

3.  Completion pneumonectomy: outcomes for benign and malignant indications.

Authors:  Varun Puri; Andrew Tran; Jennifer M Bell; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers
Journal:  Ann Thorac Surg       Date:  2013-05-03       Impact factor: 4.330

4.  Sulforaphane-cysteine-induced apoptosis via phosphorylated ERK1/2-mediated maspin pathway in human non-small cell lung cancer cells.

Authors:  Kai Lin; Ronghui Yang; Zhongnan Zheng; Yan Zhou; Yang Geng; Yabin Hu; Sai Wu; Wei Wu
Journal:  Cell Death Discov       Date:  2017-07-03

5.  The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.

Authors:  Long Jiang; Jia Huang; Shanshan Jiang; Wenwen Rong; Yaofeng Shen; Chongwu Li; Yu Tian; Junwei Ning; Xiaoke Chen; Yunhai Yang; Zhengping Ding; Ziming Li; Qingquan Luo
Journal:  Cancer Immunol Immunother       Date:  2021-01-29       Impact factor: 6.968

6.  Implementing an enhanced recovery after thoracic surgery programme in the Netherlands: a qualitative study investigating facilitators and barriers for implementation.

Authors:  Erik M von Meyenfeldt; Femke van Nassau; Carlijn T I de Betue; L Barberio; Wilhelmina H Schreurs; Geertruid M H Marres; H Jaap Bonjer; Johannes Anema
Journal:  BMJ Open       Date:  2022-01-05       Impact factor: 2.692

7.  Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer.

Authors:  Yan Hu; Si-Ying Ren; Ruo-Yao Wang; Chao Zeng; Ji-Na Li; Peng Xiao; Fang Wu; Feng-Lei Yu; Wen-Liang Liu
Journal:  Front Oncol       Date:  2021-10-06       Impact factor: 6.244

8.  Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.

Authors:  Tao Hong; Teng Sun; Miao Zhang; Xinlong Liu; Yanliang Yuan; Ponnie Robertlee Dolo; Bi Chen; Hao Zhang
Journal:  Thorac Cancer       Date:  2021-08-30       Impact factor: 3.500

9.  Cost-Effectiveness of Artificial Intelligence Support in Computed Tomography-Based Lung Cancer Screening.

Authors:  Sebastian Ziegelmayer; Markus Graf; Marcus Makowski; Joshua Gawlitza; Felix Gassert
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

10.  Cancer resection rates, socioeconomic deprivation, and geographical access to surgery among urban, suburban, and rural populations across Canada.

Authors:  Blake Byron Walker; Nadine Schuurman; Chuck K Wen; Saad Shakeel; Laura Schneider; Christian Finley
Journal:  PLoS One       Date:  2020-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.